Both drugs function by binding to estrogen receptors on cells. Tamoxifen acts as an estrogen antagonist in breast tissue, blocking the hormone's ability to stimulate the growth of breast cancer cells. Raloxifene, on the other hand, has estrogen-agonistic effects on bone and lipid metabolism but antagonistic effects on breast and uterine tissues.
